Daily PubMed evidence board
Regulatory T-cell based therapies for acute lung injury: a systematic review and meta-analysis.
This systematic review pooled animal studies and two early human studies to evaluate regulatory T-cell (Treg) therapies for acute lung injury and ARDS. In…
Signal score47Research triage score
CertaintyLowVerify in full text
PMID42246928Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review pooled animal studies and two early human studies to evaluate regulatory T-cell (Treg) therapies for acute lung injury and ARDS. In animal models, giving Tregs reduced measured lung tissue damage and lowered inflammatory markers in lung fluid. The two small clinical studies focused on safety and tolerability and did not provide enough data to judge effectiveness in patients. The authors conclude Treg therapy shows therapeutic potential, but more and better clinical trials are needed before this could change care.
Why it matters
- ARDS (acute respiratory distress syndrome) is a high-mortality inflammatory lung condition with few proven targeted therapies; this review synthesizes preclinical and early clinical evidence for a candidate cellular therapy (regulatory T-cells, Tregs).
- The meta-analysis of animal studies reports large standardized reductions in histological lung injury and decreases in bronchoalveolar lavage pro-inflammatory cytokines, protein, total cells, and neutrophils - outcomes directly relevant to ARDS pathophysiology.
- Two early-phase clinical studies (safety/tolerability) were identified, suggesting translational momentum but insufficient clinical efficacy evidence to change practice.
- If findings replicate in rigorous clinical trials, Treg therapies could shift ARDS treatment strategies toward immunomodulation; however, preclinical-to-clinical gaps and sparse clinical data mean this is a monitoring/prioritization signal, not an implementation trigger.
Primary outcomes
- Histological lung injury (preclinical)
- Mortality (clinical)
Effect summary
Meta-analysis of animal studies reported sizable reductions in histological lung injury for Treg-treated animals versus controls (≤7 days SMD = -2.06 [95% CI -2.96, -1.15]; >7 days SMD = -2.18 [95% CI -3.28, -1.08]). Tregs also reduced bronchoalveolar lavage pro-inflammatory cytokines, total protein, total cells, and neutrophil counts. Clinical data were limited to early-phase safety/tolerability studies; no clinical efficacy meta-analysis was possible from the abstract.
Benefit-cost lens
| Quick take | Promising preclinical signal for Treg cellular therapy in ALI/ARDS, but critical data (absolute clinical effects, costs, scalable delivery, harms) are missing for any credible benefit-cost claim. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based on PubMed metadata and abstract only; assumes reported meta-analytic effect sizes are from heterogeneous preclinical models and that clinical data are limited to early-phase safety studies. Full text needed to validate methods, risk of bias, and applicability. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Higher uncertainty |
| Notes | Assessment derived from PubMed abstract only. No access to full-text methods, selection criteria, study-level risk-of-bias assessments, or heterogeneity analyses; preclinical heterogeneity and publication bias are plausible. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review of methods and outcomes, standardized definitions for ARDS endpoints, GMP-grade cell manufacturing capacity, regulatory approvals, trial infrastructure at tertiary centers, trained clinical and research personnel, and cost modeling. |
|---|---|
| Equity impact | Unclear; cell therapies often require specialized manufacturing and delivery that may limit access and exacerbate disparities unless deliberately addressed in trial and rollout planning. |
| Harms | Abstract reports safety/tolerability support in early-phase clinical studies but provides no detailed adverse event rates; comprehensive harms assessment requires full-text clinical reports. |
| Replication | Unknown from automated PubMed triage; replication in randomized clinical trials not reported in abstract. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.